India’s cough syrup market, worth over ₹21,800 crore in 2024, is expanding rapidly amid rising respiratory illnesses and pollution. While this growth fuels lucrative opportunities for pharmaceutical companies—both large multinationals and smaller domestic players—it simultaneously exposes alarming risks to public health due to widespread irrational drug combinations and substandard quality control, especially among smaller manufacturers.
The Profit Behind the Puff
The market’s rising demand, estimated to grow at a steady CAGR near 6%, is driven by chronic respiratory diseases and easy availability of cough syrups in retail pharmacies and online. Top brands rake in significant revenue, with the organised sector holding a major share, but nearly one-third of the market is served by SMEs with comparatively lax oversight. The unchecked proliferation of fixed-dose combinations with questionable therapeutic rationale further boosts sales volumes despite questionable clinical benefit.[1][2][6]
Free Membership Required
You must be a Free member to access this content.
